TY - JOUR
T1 - Targeting lung cancer stem cells
T2 - Research and clinical impacts
AU - Zakaria, Norashikin
AU - Satar, Nazilah Abdul
AU - Halim, Noor Hanis Abu
AU - Ngalim, Siti Hawa
AU - Yusoff, Narazah Mohd
AU - Lin, Juntang
AU - Yahaya, Badrul Hisham
N1 - Publisher Copyright:
© 2017 Zakaria, Satar, Abu Halim, Ngalim, Yusoff, Lin and Yahaya.
PY - 2017/5/5
Y1 - 2017/5/5
N2 - Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one of two types of lung cancer, accounts for 85-90% of all lung cancers. Despite advances in therapy, lung cancer still remains a leading cause of death. Cancer relapse and dissemination after treatment indicates the existence of a niche of cancer cells that are not fully eradicated by current therapies. These chemoresistant populations of cancer cells are called cancer stem cells (CSCs) because they possess the self-renewal and differentiation capabilities similar to those of normal stem cells. Targeting the niche of CSCs in combination with chemotherapy might provide a promising strategy to eradicate these cells. Thus, understanding the characteristics of CSCs has become a focus of studies of NSCLC therapies.
AB - Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one of two types of lung cancer, accounts for 85-90% of all lung cancers. Despite advances in therapy, lung cancer still remains a leading cause of death. Cancer relapse and dissemination after treatment indicates the existence of a niche of cancer cells that are not fully eradicated by current therapies. These chemoresistant populations of cancer cells are called cancer stem cells (CSCs) because they possess the self-renewal and differentiation capabilities similar to those of normal stem cells. Targeting the niche of CSCs in combination with chemotherapy might provide a promising strategy to eradicate these cells. Thus, understanding the characteristics of CSCs has become a focus of studies of NSCLC therapies.
KW - Cancer stem cells
KW - Lung cancer
KW - Neoplastic stem cells
KW - Non-small cell lung cancer
KW - Surface markers
KW - Therapeutics
UR - https://www.scopus.com/pages/publications/85020103778
U2 - 10.3389/fonc.2017.00080
DO - 10.3389/fonc.2017.00080
M3 - Short survey
SN - 2234-943X
VL - 7
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - MAY
M1 - 80
ER -
